and now, a fascinating new article in the journal of clinical microbiology by soya sam and angela caliendo at lifespan, colleen kraft at emory, and colleagues.
the researchers were focused on accurate and rapid diagnosis for acute respiratory viral infections.
they evaluated performance characteristics of the so-called “panther fusion assay” for the detection of influenza A and B, respiratory syncytial virus (RSV), parainfluenza viruses 1 to 3 (Para 1 to 3), human metapneumovirus (hMPV), rhinovirus (RV), and adenovirus (Adeno).
the study found that the panther fusion provided laboratories with an automated system to test for a broad array of viral respiratory pathogens.
the questions i see involve cost, training, and most importantly, the question of “what’s next.” if microbiology laboratories spend lots of money buying the panther fusion assay, will it be obsolete in several years? what is the strategy to make sure the return on investment is high enough? this requires doctors and lab administrators to think like mba’s.
If you found this post useful, please continue the discussion. go to “leave a reply” at the bottom of this page. thanks!
dr. phil lederer